Next Article in Journal
Association of Plasma Branched-Chain and Aromatic Amino Acids with Reduction in Kidney Function Evaluated in Apparently Healthy Adults
Next Article in Special Issue
Clinical, Histological, and Genetic Features of 25 Patients with Autosomal Dominant Progressive External Ophthalmoplegia (ad-PEO)/PEO-Plus Due to TWNK Mutations
Previous Article in Journal
Improvements in Quality of Life and Thyroid Parameters in Hypothyroid Patients on Ethanol-Free Formula of Liquid Levothyroxine Therapy in Comparison to Tablet LT4 Form: An Observational Study
Previous Article in Special Issue
Cerebellar White Matter Abnormalities in Charcot–Marie–Tooth Disease: A Combined Volumetry and Diffusion Tensor Imaging Analysis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Mitochondrial Medicine in the COVID-19 Era

Unit of Neurology, San Luca Hospital, Via Lippi-Francesconi, 55100 Lucca, Italy
J. Clin. Med. 2021, 10(22), 5235; https://doi.org/10.3390/jcm10225235
Submission received: 1 November 2021 / Accepted: 8 November 2021 / Published: 10 November 2021
(This article belongs to the Special Issue Mitochondrial Disorders: Molecular, Clinical and Therapeutic Advances)
Mitochondrial disorders are a remarkably complex group of diseases caused by impairment of the mitochondrial respiratory chain (or electron transport chain). Phenotypes may range from isolated myopathy to multisystem disorders, with highly variable age of onset, severity, and progression. The genetic defect can be located in the mitochondrial (mtDNA) or the nuclear genome (nDNA). Mitochondrial diseases due to mtDNA mutations are peculiar in human genetics, following different inheritance laws than nuclear mutations [1].
If we consider that muscular involvement is the core feature of these disorders and that transient muscular dysfunction is common during COVID-19 even in the general population [2], we can easily understand the increased concerns of mitochondrial patients during the pandemic period.
However, by searching PubMed with the terms “mitochondrial, COVID* OR mitochondrial, coronavirus*”, to date (3 November 2021), there is no empirical evidence of a heightened risk for a severe outcome of COVID-19 in these subjects, except from an isolated report of a patient with pre-existing severe MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) further complicated by COVID-19 [3].
A retrospective Italian case series on 27 mitochondrial patients infected by SARS-CoV-2 revealed that most patients had mild infections (85%) and were treated at home. Only one patient died because of COVID-19 pneumonia. Therefore, individuals with a mitochondrial disorder appeared to be similarly affected by SARS-CoV-2 infection compared with the general population [4].
The COVID-19 pandemic may also have had indirect effects on mitochondrial patients, e.g., by losing the multisystem follow-up checks or even by increasing alcohol consumption and the number of cigarettes smoked during the recent lockdowns. This latter factor may have led to the clinical expression of a previously asymptomatic Leber hereditary optic neuropathy in at least some individuals [5].
Patient care standards for mitochondrial disorders, including, for instance, cardio-respiratory and nutritional follow-up, must also be provided during pandemics (with telemedicine facilities when appropriate). Furthermore, mitochondrial patients must be offered age-appropriate vaccination [6], including vaccines against COVID-19, that are as safe for them as for the general population.
In this context, this Special Issue (“Mitochondrial Disorders: Molecular, Clinical and Therapeutic Advances”, https://www.mdpi.com/journal/jcm/special_issues/Mitochondrial_Clinical) (accessed on 1 November 2021). aims to clarify the molecular basis, the clinical spectrum, the diagnostic approach, and the treatment advances of mitochondrial disorders. We do not fully know mitochondrial diseases yet, but we are beginning to unravel their complexity.

Funding

This research received no external funding.

Conflicts of Interest

The author declares no conflict of interest.

References

  1. Orsucci, D.; Ienco, E.C.; Rossi, A.; Siciliano, G.; Mancuso, M. Mitochondrial Syndromes Revisited. J. Clin. Med. 2021, 10, 1249. [Google Scholar] [CrossRef] [PubMed]
  2. Orsucci, D.; Trezzi, M.; Anichini, R.; Blanc, P.; Barontini, L.; Biagini, C.; Capitanini, A.; Comeglio, M.; Corsini, P.; Gemignani, F.; et al. Increased Creatine Kinase May Predict A Worse COVID-19 Outcome. J. Clin. Med. 2021, 10, 1734. [Google Scholar] [CrossRef] [PubMed]
  3. Sen, K.; Harrar, D.; Hahn, A.; Wells, E.M.; Gropman, A.L. Management considerations for stroke-like episodes in MELAS with concurrent COVID-19 infection. J. Neurol. 2021, 268, 3988–3991. [Google Scholar] [CrossRef] [PubMed]
  4. Mancuso, M.; La Morgia, C.; Valentino, M.L.; Ardissone, A.; Lamperti, C.; Procopio, E.; Garone, C.; Siciliano, G.; Musumeci, O.; Toscano, A.; et al. SARS-CoV-2 infection in patients with primary mitochondrial diseases: Features and outcomes in Italy. Mitochondrion 2021, 58, 243–245. [Google Scholar] [CrossRef] [PubMed]
  5. Zaslavsky, K.; Margolin, E.A. Leber’s Hereditary Optic Neuropathy in Older Individuals Due to Increased Alcohol Consumption During the COVID-19 Pandemic. J. Neuro-Ophthalmol. 2021, 41, 316–320. [Google Scholar] [CrossRef] [PubMed]
  6. Orsucci, D.; Ienco, E.C.; Siciliano, G.; Mancuso, M. Mitochondrial disorders and drugs: What every physician should know. Drugs Context 2019, 8, 1–16. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Orsucci, D. Mitochondrial Medicine in the COVID-19 Era. J. Clin. Med. 2021, 10, 5235. https://doi.org/10.3390/jcm10225235

AMA Style

Orsucci D. Mitochondrial Medicine in the COVID-19 Era. Journal of Clinical Medicine. 2021; 10(22):5235. https://doi.org/10.3390/jcm10225235

Chicago/Turabian Style

Orsucci, Daniele. 2021. "Mitochondrial Medicine in the COVID-19 Era" Journal of Clinical Medicine 10, no. 22: 5235. https://doi.org/10.3390/jcm10225235

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop